Table 2 Patient characteristics longitudinal analysis
N = 11 | |
|---|---|
Age at Tx (years)a | 65.4 (47–75) |
Gender (male) | 8 (72.7%) |
Years between Tx and first cSCCa | 2.6 (1.1–11.5) |
Years between Tx and post-Tx samplea | 2.1 (0.3–13.0) |
CMV acceptor | |
Negative | 4 (36.4%) |
Positive | 7 (63.6%) |
CMV donor | |
Negative | 7 (63.6%) |
Positive | 4 (36.4%) |
HLA mismatchesa | 2 (0–6) |
Type of immunosuppression directly after transplantation | |
Corticosteroids | 10 (90.9%) |
Tacrolimus | 10 (90.9%) |
MMF | 10 (90.9%) |
Cyclosporine | 1 (9.1%) |
Sirolimus | 1 (9.1%) |
Basiliximab induction | 3 (27.3%) |
ATG induction | 1 (9.1%) |
ESRD diagnosis | |
Polycystic kidney | 5 (45.5%) |
Hypertension | 1 (9.1%) |
Other | 5 (45.5%) |
Dialysis pre-transplantation | |
Yes | 8 (72.7%) |
No | 3 (27.3%) |